Clinical TrialJul 1, 2026, 07:36 AM
iBio's IBIO-610 Shows Near-Complete Activin E Inhibition in NHP Study
AI Summary
iBio announced new preclinical data for its IBIO-610 Activin E antibody candidate from an obese non-human primate study. A single dose of IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks. The data also showed IBIO-610's potential for fat-selective weight loss while preserving lean mass, and when combined with semaglutide, it reduced lean mass loss by 73% compared to semaglutide alone. These findings support its potential as a stand-alone or complementary therapy for obesity.
Key Highlights
- Single dose of IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks in obese NHPs.
- Active Activin E levels remained suppressed through eight weeks, supporting an infrequently dosed approach.
- IBIO-610 demonstrated potential for fat-selective weight loss while preserving lean mass.
- When combined with semaglutide, IBIO-610 drove greater visceral and total fat loss.
- Reduced lean mass loss by 73% when combined with semaglutide versus semaglutide alone.
- Full data to be presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD).
Price Impact
More from IBIO